Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma

References

• ArmitageJOThe aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and managementAm J Hematol201287551151922508369
   PubMed Web of Science ®Google Scholar
• ParkSKoYHPeripheral T cell lymphoma in AsiaInt J Hematol201499322723924481942
   PubMed Web of Science ®Google Scholar
• AbouyabisANShenoyPJSinhaRFlowersCRLechowiczMJA systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphomaISRN Hematol2011201162392422084700
   PubMedGoogle Scholar
• VeikkolaTAlitaloKVEGFs, receptors and angiogenesisSemin Cancer Biol19999321122010343072
   PubMed Web of Science ®Google Scholar
• JørgensenJMSørensenFBBendixKAngiogenesis in non-Hodgkin’s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypesLeuk Lymphoma200748358459517454603
   PubMed Web of Science ®Google Scholar
• PiccalugaPPAgostinelliCCalifanoAGene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulationCancer Res20076722107031071018006812
   PubMed Web of Science ®Google Scholar
• ZhangWWangLZhouDCuiQZhaoDWuYExpression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specifiedLeuk Lymphoma20115214652
   PubMed Web of Science ®Google Scholar
• JørgensenJMSørensenFBBendixKExpression level, tissue distribution pattern, and prognostic impact of vascular endothelial growth factors VEGF and VEGF-C and their receptors Flt-1, KDR, and Flt-4 in different subtypes of non-Hodgkin lymphomasLeuk Lymphoma200950101647166019701853
   PubMedGoogle Scholar
• ShichiriMHirataYAntiangiogenesis signals by endostatinFASEB J200115610441053
   Google Scholar
• YinGLiuWAnPEndostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritisMol Ther200255 Pt 154755411991745
   PubMedGoogle Scholar
• SudhakarASugimotoHYangCLivelyJZeisbergMKalluriRHuman tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrinsProc Natl Acad Sci U S A200310084766477112682293
   PubMed Web of Science ®Google Scholar
• KimYMHwangSKimYMEndostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1J Biol Chem200227731278722787912029087
   PubMed Web of Science ®Google Scholar
• LingYYangYLuNEndostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cellsBiochem Biophys Res Commun20073611798417644065
   PubMed Web of Science ®Google Scholar
• O’ReillyMSBoehmTShingYEndostatin: an endogenous inhibitor of angiogenesis and tumor growthCell19978822772859008168
   PubMed Web of Science ®Google Scholar
• SunYWangJLiuYResults of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients [abstract]J Clin Oncol20052316S7138
   Google Scholar
• ChenJYaoQLiDNeoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II studyBMC Cancer20131324823693018
   PubMed Web of Science ®Google Scholar
• XuRMaNWangFResults of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancerOnco Targets Ther2013692592923926435
   PubMed Web of Science ®Google Scholar
• GaoSRLiLMXiaHPWangGMXuHYWangARClinical observation on recombinant human endostatin combined with chemotherapy for advanced gastrointestinal cancerAsian Pac J Cancer Prev20151694037404025987082
   PubMedGoogle Scholar
• LiBLHuXLZhaoXHSunHGZhouCYZhangYEndostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: a clinical studyJ Chemother201527530130625873343
   PubMed Web of Science ®Google Scholar
• CuiCMaoLChiZA phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanomaMol Ther20132171456146323670576
   PubMed Web of Science ®Google Scholar
• ChesonBDHorningSJCoiffierBReport of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working GroupJ Clin Oncol1999174124410561185
   PubMed Web of Science ®Google Scholar
• SimonROptimal two-stage designs for phase II clinical trialsControl Clin Trials19891011102702835
   PubMedGoogle Scholar
• KarakasTBergmannLStutteHJPeripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomasLeuk Lymphoma1996241–21211299049968
   PubMed Web of Science ®Google Scholar
• GisselbrechtCGaulardPLepageEPrognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA)Blood199892176829639502
   PubMed Web of Science ®Google Scholar
• GanjooKHongFHorningSJBevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)Leuk Lymphoma201455476877223786456
   PubMed Web of Science ®Google Scholar
• ZhaoSZhangLZhangMAngioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patientsMed Oncol20122942311231622038726
   PubMedGoogle Scholar
• ZhaoWLMourahSMounierNVascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progressionLab Invest200484111512151915311211
   PubMed Web of Science ®Google Scholar
• MouradNMounierNBrièreJClinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trialsBlood200811194463447018292286
   PubMed Web of Science ®Google Scholar
• FedericoMRudigerTBelleiMClinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma projectJ Clin Oncol201331224024622869878
   PubMed Web of Science ®Google Scholar
• XuBLiuPNo survival improvement for patients with angioimmunoblastic T-cell lymphoma over the past two decades: a population-based study of 1207 casesPLoS One201493e9258524651162
   PubMedGoogle Scholar
• TokunagaTShimadaKYamamotoKRetrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in JapanBlood2012119122837284322308294
   PubMed Web of Science ®Google Scholar
• KonstantinouKYamamotoKIshibashiFAngiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphomaBr J Haematol2009144569670419120365
   PubMed Web of Science ®Google Scholar
• XuanZXLiLNZhangQFully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growthInt J Oncol20144562411242025269419
   PubMedGoogle Scholar
• LiTLiuXShenQSalinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesisOncotarget2016718265802659227058891
   PubMedGoogle Scholar
• ShenGLiYDuTSKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacyNeoplasma201259548649322668017
   PubMedGoogle Scholar
• WilkeHMuroKVan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• EliceFRodeghieroFSide effects of anti-angiogenic drugsThromb Res2012129Suppl 1S50S5322682133
   PubMed Web of Science ®Google Scholar
• MaitlandMLKaszaKEKarrisonTAmbulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentClin Cancer Res200915196250625719773379
   PubMed Web of Science ®Google Scholar